companies innovating obesity treatment glp-1 drugs 2025 Potential Emerging Therapies in the Space FDA-Approved Obesity Medications Timeline: Evolution

The real shift isnt just the molecule its usability

With the participation of researchers from the Paul Langerhans Institute Dresden (PLID), partner at the German Center for Diabetes Research, a GLP-1 receptor agonist in the form of tablets could for the first time be compared with the most common second-line therapy of T2D, a DPP-IV inhibitor

Learn what they contain, what the science actually says, and what truly supports people using GLP-1 medications.

Primary outcomes included changes in TTR, INR, and INR recheck frequency

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Check our Semaglutide weight loss dosage chart to find the right dose for safe and effective weight management